Heidemann, J.; Binion, D. G.; Domschke, W.; Kucharzik, T.
October 2006
Gut;Oct2006, Vol. 55 Issue 10, p1497
Academic Journal
Angiogenesis is a crucial process involved in numerous physiological and pathophysiological settings. During the past three decades, the field of turnout associated angiogenesis has been the focus of a plethora of basic research projects and clinical studies. Tumour associated neovessels satisfying the increased demand of oxygen and nutrients in malignant tumours are now emerging as specific targets for novel antineoplastic agents. This article discusses the present data on antiangiogenic treatment of human gastrointestinal malignancies, including gastric, pancreatic, and colorectal adenocarcinoma, and outlines potential future perspectives, such as development of surrogate markers of angiogenesis.


Related Articles

  • Evidence of Efficacy: Researchers Investigating Markers for Angiogenesis Inhibitors. Brower, Vicki // JNCI: Journal of the National Cancer Institute;10/1/2003, Vol. 95 Issue 19, p1425 

    Focuses on the results of the phase III trial for the angiogenesis inhibitor drug, Avastin for patients with metastatic colorectal cancer. Indications of extended patient longevity; Analysis of reliable biomarkers for treatment with the drug.

  • TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. Cernaianu, Grigore; Frank, Sibylle; Erbstößer, Katrin; Leonhardt, Sandy; Cross, Michael; McIvor, Zoe; Scholz, Gabriele; Dansranjavin, Temuujin; Celik, Ilhan; Tannapfel, Andrea; Wittekind, Christian; Troebs, Ralf-Bodo; Rothe, Karin; Bennek, Joachim; Hauss, Johann; Witzigmann, Helmut // International Journal of Colorectal Disease;Mar2006, Vol. 21 Issue 2, p143 

    The article presents information on a study which examined the effect of the angiogenesis inhibitor TNP-470 on the early stages of tumor establishment. The study used green fluorescent protein-transfected murine CT-26 or pancreatic adenocarcinoma cells. The study highlighted the failure of...

  • Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility. Kläver, Ruth; Sánchez, Victoria; Damm, Oliver S.; Redmann, Klaus; Lahrmann, Elisabeth; Sandhowe-Klaverkamp, Reinhild; Rohde, Christian; Wistuba, Joachim; Ehmcke, Jens; Schlatt, Stefan; Gromoll, Jörg // PLoS ONE;Feb2015, Vol. 10 Issue 2, p1 

    Establishment and maintenance of the correct epigenetic code is essential for a plethora of physiological pathways and disturbed epigenetic patterns can provoke severe consequences, e.g. tumour formation. In recent years, epigenetic drugs altering the epigenome of tumours actively have been...

  • Individualizing chemotherapeutic treatment of colorectal cancer. Crews, Kristine R. // American Journal of Health-System Pharmacy;May2006 Supplement, Vol. 63, pS12 

    Purpose. Patient-specific factors that enter into decisions about the chemotherapy used to treat colorectal cancer are illustrated in several case studies. Summary. Genetic polymorphisms in genes that encode drug-metabolizing enzymes may affect the disposition and the risk for toxicity from...

  • A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Jeung, H.-C.; Rha, S. Y.; Cho, B. C.; Yoo, N. C.; Roh, J. K.; Roh, W. J.; Chung, H. C.; Ahn, J. B. // British Journal of Cancer;12/18/2006, Vol. 95 Issue 12, p1637 

    This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m-2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the...

  • Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice. Goel, Gaurav; Weijing Sun // Journal of Hematology & Oncology;Jul2015, Vol. 8 Issue 1, p1 

    The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

  • Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo. Qin Pan; Hongming Pan; Haizhou Lou; Yinghua Xu; Lu Tian // Cancer Cell International;2013, Vol. 13 Issue 1, p1 

    Background: Angiogenesis has been an attractive target for drug therapy. Aloin (AL), an natural compound derived from Aloe barbadensis Miller leaves, has been shown to possess anti-cancer potential activities. However, its roles in tumor angiogenesis and the involved molecular mechanism are...

  • A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Dragovich, Tomislav; Mendelson, David; Kurtin, Sandra; Richardson, Kelly; Hoff, Daniel; Hoos, Axel // Cancer Chemotherapy & Pharmacology;Dec2006, Vol. 58 Issue 6, p759 

    Purpose: L-NDDP (AroplatinTM) is a liposomal formulation of cis- bis-neodecanoato- trans- R, R-1,2-diaminocyclohexane platinum (II), a structural analogue of oxaliplatin. In a Phase 1 trial, the maximum tolerated dose (MTD) of L-NDDP was 312.5 mg/m2 with myelosuppression as dose limiting...

  • Generalized Juvenile Polyposis with Carcinoma. Bentley, Edward; Chandrasoma, Parakrama; Radin, Randolph; Cohen, Hartley // American Journal of Gastroenterology;Nov1989, Vol. 84 Issue 11, p1456 

    Generalized juvenile polyposis usually is not associated with an increased risk for gastrointestinal carcinoma. A subgroup of patients, however, have juvenile polyps with adenomatous features. A case report of juvenile polyposis, together with adenocarcinoma of the colon and review of the...


Read the Article


Sign out of this library

Other Topics